- Conditions
- Epilepsy
- Interventions
- Progesterone Lozenges, Matched Placebo Lozenges
- Biological · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2185–2208
of 10,871
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
- Interventions
- Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 7 more
- Conditions
- Multiple Sclerosis
- Interventions
- BIIB033 (opicinumab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 51
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
- Conditions
- Leukemia, Other
- Interventions
- Not listed
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • Miami Beach, Florida • Rochester, Minnesota + 2 more
- Conditions
- Acute Kidney Injury
- Interventions
- QPI-1002, Placebo
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more
- Conditions
- Post Operative Surgical Site Infection
- Interventions
- Standard of care, Vancomycin and Tobramycin
- Drug
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 31
- States / cities
- Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
- Conditions
- Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma, Neuroblastoma, Wilms Tumor, Malignant Peripheral Nerve Sheath Tumor, Clival Chordoma, Non-CNS Solid Tumors
- Interventions
- HSV1716
- Biological
- Lead sponsor
- Timothy Cripe
- Other
- Eligibility
- 7 Years to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 341
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 240 more
- Conditions
- Heart Failure
- Interventions
- HM II (HeartMate II LVAD), OMM (Optimal Medical Management)
- Device · Drug
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more
- Conditions
- Heart Failure, Cardiomyopathy
- Interventions
- Cardiac resynchronization therapy device
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 48 more
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- NSCLC
- Interventions
- ctDNA, tumor NGS
- Diagnostic Test
- Lead sponsor
- Lung Cancer Mutation Consortium
- Network
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 25
- States / cities
- Davis, California • Los Angeles, California • Orange, California + 16 more
- Conditions
- Advanced Melanoma
- Interventions
- Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy
- Biological · Drug
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 50
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 8,061 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 146
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 23
- States / cities
- La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Severe Sepsis
- Interventions
- Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 16
- States / cities
- Sacramento, California • Colorado Springs, Colorado • Denver, Colorado + 12 more
- Conditions
- Delirium, Impaired Cognition, Long Term Psychologic Disorders
- Interventions
- Haloperidol, Ziprasidone, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 16
- States / cities
- Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
- Conditions
- Myopia
- Interventions
- Atropine, Placebo Eyedrops
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boise, Idaho + 10 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 57
- States / cities
- Los Angeles, California • San Francisco, California • San Jose, California + 34 more
- Conditions
- COVID-19
- Interventions
- RD-X19, Sham
- Device
- Lead sponsor
- EmitBio Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 48
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 42 more
- Conditions
- Progressive Keratoconus, Corneal Ectasia
- Interventions
- Riboflavin, Placebo
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Dublin, Ohio
- Conditions
- BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
- Interventions
- Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib
- Drug · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Columbus, Ohio • Houston, Texas
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
- Conditions
- Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
- Interventions
- Ranibizumab, Saline
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more